ACAD
40.19
-0.63
-1.54%
AEMD
8.74
+0.11
+1.27%
APRI
1.64
+0.02
+1.23%
ARNA
3.985
-0.025
-0.623%
ATEC
1.36
0.00
0.00%
CNAT
5.46
+0.11
+2.06%
CRXM
0.49
+0.02
+5.15%
CYTX
0.732
+0.043
+6.1956%
DXCM
71.27
-0.37
-0.52%
GNMK
9.37
+0.11
+1.19%
HALO
17.68
-0.14
-0.79%
ILMN
208.62
-0.85
-0.41%
INNV
0.153
+0.003
+1.6667%
INO
8.58
+0.19
+2.26%
ISCO
0.05
0.00
0.00%
ISIS
66.71
-1.01
-1.49%
LGND
88.15
+0.89
+1.02%
LPTN
0.291
-0.009
-3.032%
MBVX
2.26
-0.08
-3.42%
MEIP
1.89
-0.02
-1.05%
MNOV
3.95
0.00
0.00%
MRTX
36.18
+2.43
+7.20%
MSTX
0.54
+0.03
+5.70%
NBIX
42.76
-0.18
-0.42%
NUVA
49.62
+0.84
+1.72%
ONCS
0.233
0.00
0.00%
ONVO
4.96
+0.17
+3.55%
OREX
4.92
-0.01
-0.20%
OTIC
24.33
-0.13
-0.53%
QDEL
22.24
-0.17
-0.76%
RCPT
164.83
-0.82
-0.50%
RGLS
13.58
-0.05
-0.37%
RMD
58.65
+0.55
+0.95%
SCIE
0.018
0.00
0.00%
SPHS
1.11
+0.03
+2.78%
SRNE
13.8
+0.76
+5.83%
TROV
11
-0.19
-1.70%
VICL
0.955
+0.033
+3.534%
VOLC
17.99
0.00
0.00%
ZGNX
1.49
+0.02
+1.36%
ACAD
40.19
-0.63
-1.54%
AEMD
8.74
+0.11
+1.27%
APRI
1.64
+0.02
+1.23%
ARNA
3.985
-0.025
-0.623%
ATEC
1.36
0.00
0.00%
CNAT
5.46
+0.11
+2.06%
CRXM
0.49
+0.02
+5.15%
CYTX
0.732
+0.043
+6.1956%
DXCM
71.27
-0.37
-0.52%
GNMK
9.37
+0.11
+1.19%
HALO
17.68
-0.14
-0.79%
ILMN
208.62
-0.85
-0.41%
INNV
0.153
+0.003
+1.6667%
INO
8.58
+0.19
+2.26%
ISCO
0.05
0.00
0.00%
ISIS
66.71
-1.01
-1.49%
LGND
88.15
+0.89
+1.02%
LPTN
0.291
-0.009
-3.032%
MBVX
2.26
-0.08
-3.42%
MEIP
1.89
-0.02
-1.05%
MNOV
3.95
0.00
0.00%
MRTX
36.18
+2.43
+7.20%
MSTX
0.54
+0.03
+5.70%
NBIX
42.76
-0.18
-0.42%
NUVA
49.62
+0.84
+1.72%
ONCS
0.233
0.00
0.00%
ONVO
4.96
+0.17
+3.55%
OREX
4.92
-0.01
-0.20%
OTIC
24.33
-0.13
-0.53%
QDEL
22.24
-0.17
-0.76%
RCPT
164.83
-0.82
-0.50%
RGLS
13.58
-0.05
-0.37%
RMD
58.65
+0.55
+0.95%
SCIE
0.018
0.00
0.00%
SPHS
1.11
+0.03
+2.78%
SRNE
13.8
+0.76
+5.83%
TROV
11
-0.19
-1.70%
VICL
0.955
+0.033
+3.534%
VOLC
17.99
0.00
0.00%
ZGNX
1.49
+0.02
+1.36%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.